IP Library Granted Patent US 11,028,048
Granted Patent B2
US 11,028,048 · App. 16/777,273 · Granted Jun 8, 2021

Heterocyclic compound and use thereof

Inventors: Yasushi Hattori (Kanagawa, JP); Yuhei Miyanohana (Kanagawa, JP); Yuichi Kajita (Kanagawa, JP); Tatsuki Koike (Kanagawa, JP); Yasutaka Hoashi (Kanagawa, JP); Norihito Tokunaga (Kanagawa, JP); Alexander Martin Pawliczek (Kanagawa, JP); Tsuneo Oda (Kanagawa, JP); Tohru Miyazaki (Kanagawa, JP); Marilena Pira (Kanagawa, JP); Javier Miguelez-Ramos (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D207/14C07D407/08C07D417/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,028,048
App. No.
16/777,273
Granted
Jun 8, 2021
Kind
B2
Abstract

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Claims (9)

1. N′-{(2 S,3R,4S)-1-(azetidine-1-carbonyl)-4-fluoro-2-[(2-fluoro-3 methyl[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}-N,N-dimethyl sulfuric diamide or a salt thereof.

2. N-[(2S,3R)-2-[(2,3′-difluoro[1,1′-biphenyl]-3-yl)methyl]-4,4-difluoro-1-(2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide or a salt thereof.

3. N-{(2S,3R)-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3′,5′-trifluoro[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide or a salt thereof.

4. N-{(2S,3R)-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3′,5′-trifluoro[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}methanesulfonamide or a salt thereof.

5. N-{(2S,3R)-1-(bicyclo[1.1.1]pentane-1-carbonyl)-4,4-difluoro-2-[(2,3′,5′-trifluoro[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}methanesulfonamide or a salt thereof.

6. N-{(2S,3R)-1-(cyclopropanecarbonyl)-4,4-difluoro-2-[(2,3′,5′-trifluoro[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide or a salt thereof.

7. N-{(2S,3R)-4,4-difluoro-1-((1s,3R)-3-fluorocyclobutane-1-carbonyl)-2-[(2,3′,5′-trifluoro[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide or a salt thereof.

8. N-{(2S,3R)-4,4-difluoro-1-((1s,3R)-3-fluorocyclobutane-1-carbonyl)-2-[(2,3′,5′-trifluoro[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}methanesulfonamide or a salt thereof.

9. N′-{(2S,3R)-1-(azetidine-1-carbonyl)-4,4-difluoro-2-[(2-fluoro-3′-methyl[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}-N,N-dimethylsulfuric diamide or a salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2021
From: PIRA, MARILENA; MIGUELEZ-RAMOS, JAVIER
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055539/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2020
From: HATTORI, YASUSHI; MIYANOHANA, YUHEI; KAJITA, YUICHI; KOIKE, TATSUKI; HOASHI, YASUTAKA; TOKUNAGA, NORIHITO; PAWLICZEK, ALEXANDER MARTIN; ODA, TSUNEO; MIYAZAKI, TOHRU; ITO, YOSHITERU; TAKEUCHI, KOHEI; IMAMURA, KEISUKE; SUGIMOTO, TAKAHIRO
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 052499/0152 →
Priority Claims (1)
JP JP2019-015488 · Jan 31, 2019 · national
Continuity (1)
Related Publication 20200247747A1 · Aug 6, 2020
Cited By (5)
US 12,404,237 US 12,415,782 US 12,421,188 US 12,534,471 US 12,662,453